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Howcells coordinate inhibitionof growthanddivisionduringgeno-
toxic events is fundamental to our understanding of the origin of can-
cer. Despite increasing interest and extensive study, the mechanisms
that linkregulationofDNAsynthesisandribosomalbiogenesis remain
elusive. Recently, the tumor suppressor p14ARF (ARF) has been shown
to interact functionallywith thenucleolarproteinB23/NPM(B23) and
inhibit rRNAbiogenesis.However, themolecularbasisof theARF-B23
interaction is hitherto unclear. Here we show that a highly conserved
motif in the B23 oligomerization domain is essential for mediating
ARF binding in vivo. Mutagenesis of conserved B23 core residues
(L102A, G105A, G107A) prevented B23 from interacting with ARF.
Modelingof theB23core indicatedthat substitutions intheGSGPloop
motif couldtriggerconformationalchanges inB23therebyobstructing
ARF binding. Interestingly, the GSGP loop mutants were unstable,
defective for oligomerization, and delocalized from the nucleolus to
thenucleoplasm.B23coremutantsdisplayed increasedubiquitination
and proteasomal degradation.We conclude that the functional integ-
rity of the B23 core motif is required for stability, efficient nucleolar
localization as well as ARF binding.
The tumor suppressor ARF is often mutated in human cancer at an
overall frequency of 40%, second only to that of p53 mutations (1). This
extraordinarily high incidence of mutation of ARF is believed to be the
result of the unusual organization of the gene in the genome. The human
ARF gene resides at the chromosome 9p21 locus and, using an alternative
reading frame, shares a common exon 2 with the CDK inhibitor p16INK4a
(2–5).Themajorityofmutations at theARF-INK4a locus inhuman tumors
involve homozygous deletions of the entire locus, causing simultaneous
disruption of both genes and impairment of the twomajor tumor suppres-
sion pathways inmammalian cells, represented by the retinoblastoma pro-
teinRb and the tumor suppressor protein p53, both ofwhich are frequently
inactivated in most, if not all, human cancers (6–9). ARF expression is
elevated by stimulation fromoncogenes such asMyc, E2F1, oncogenic Ras,
adenovirus E1A, and v-Abl (10–14). Such observations led to a proposal
thatARFmediates a p53-dependent checkpoint that, in response to hyper-
proliferative oncogenic signals, induces cell cycle arrest (15). Mechanisti-
cally, ARF binds MDM2 (16, 17), inhibits MDM2-mediated p53 ubiquiti-
nation and degradation (18), and activates p53. This is attained, at least in
part, by blocking the nuclear export of both p53 andMDM2 (19, 20). Addi-
tional findings indicate that ARF has MDM2- and p53-independent func-
tions in inducing both cell cycle arrest and apoptosis (21). Recently, two
studies linked a function of ARF to ribosomal biogenesis and shed some
light on the role of ARF in the nucleolus. The first study identifiedARF as a
factor involved in inhibiting the processing of rRNA (22) and this effect of
ARFwas independentof the functionofMDM2andp53.The second study
identified that ARF physically interacts with, and functionally inhibits, the
nucleolar protein B23/NPM (a.k.a. nucleophosmin, numatrin, NO38) by
promoting B23 polyubiquitination and proteosomal degradation (23).
Taken together, these two studies establish a previously unidentified nucle-
olar function for ARF in inhibiting ribosomal biogenesis.
B23 is an abundant nucleolar protein implicated in multiple cellular
functions, including ribosome assembly and transport (24), centrosome
duplication (25), molecular chaperone activity in preventing protein
aggregation (26), and regulating the activity of p53 (27). B23 possesses
endoribonuclease activity (28, 29) and cleaves the second internal tran-
scribed spacer (ITS2) in 32 S pre-rRNA, generating mature 28 S rRNA
(30). A previous study has suggested that B23 has a tumor suppression
function through p53 (27). This conclusion was based on the observa-
tion that overexpression of B23 induces a p53-dependent cell cycle
arrest in normal fibroblast cells. Other studies, however, have linked
high level expression of B23 with uncontrolled cell growth, suggesting
that B23 may have oncogenic potential (31–33). Overexpression of B23
in NIH-3T3 cells resulted in malignant transformation and caused
tumorigenesis in nudemice (34). Such tumor cells also became resistant
to UV-induced cell cycle arrest and apoptosis (35, 36). Conversely, mice
lacking B23 die in early embryonic stages (37, 38), indicating an essential
role for B23 in embryonic development. B23 belongs to the nucleoplas-
min (Np)5 superfamily of chaperones, which also includes proteins
NO29, Npm3, ANO39, Mp62, and Np, the archetypal member of the
family (39–41). Proteins belonging to the Np family have a conserved
N-terminal core domain (Np-core). Although the exact role of the core
is unclear, recent crystal structure studies have suggested that it medi-
ates pentamer formation and histone binding (40, 42, 43). The ARF-B23
interaction has been confirmed recently, though themechanistic expla-
nation varies, by several other groups (44–46). These studies identify a
genuine functional interaction between ARF and B23 and suggest a
potential ARF-B23-rRNA pathway that, independent of the ARF-
MDM2-p53 pathway, controls ribosomal biogenesis, and modulates
growth arrest upon oncogenic insult. To gain further insights into
the functions of ARF-B23 interaction, we investigated the ARF-B23
binding in detail and this report identifies amino acid sequences down
to single residues in B23 required for ARF binding. More importantly,
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the same ARF binding essential residues in B23 were also found to be
required for B23 oligomerization, protein stability, and efficient nucle-
olar accumulation. A potential mechanism of how ARF inhibits B23
function will be discussed.
MATERIALS AND METHODS
Plasmids—pcDNA3-myc3-B23, B23-(117–294), B23-(196–294),
and B23-(1–192) constructs were previously described (23). Novel B23
deletion mutants and point mutations were constructed by conven-
tional PCR or PCR-mediated mutagenesis using pcDNA3-myc3-B23 as
a template. B23 wild type, deletion, or point mutants were cloned in
frame with GST in the pGEX-2T vector or inserted in-frame with GFP
in the EGFP-N1 vector. PCR primer sequences and details for PCR are
available upon request. All mutants were confirmed by direct DNA
sequencing. ARF constructs and adenovirus were described elsewhere
(16, 19).
Antibodies—Mousemonoclonal antibodies against B23 (Zymed Lab-
oratories), actin (MAB1501, Chemicon International), FLAG (M2,
Sigma), GST (AmershamBiosciences), and rabbit polyclonal antibodies
against Myc (used in Fig. 1, Abcam) were purchased commercially. The
affinity-purified rabbit polyclonal ARF antibody was described previ-
ously (16). Rabbit polyclonal Myc antibody was a gift from Dr. Yue
Xiong (UNC, Chapel Hill). Horseradish peroxidase-conjugated donkey
anti-mouse and anti-rabbit antibodies and rhodamine-red-conjugated
donkey anti-mouse and anti-rabbit secondary antibodies were pur-
chased from Jackson ImmunoResearch Laboratories.
Cell Lines and Transfection—U2OS (p53 wt, human osteosarcoma)
was obtained from ATCC. Cells were transfected using Effectene (Qia-
gen) according to the manufacturer’s instructions. In some experi-
ments, actinomycin D (Sigma) was dissolved in 100% ethanol as a 5 mM
stock, with a final concentration of 5 nM used for treatments (47).
MG132 (Calbiochem) was dissolved in 100% ethanol as a 10 mM stock
and a final concentration of 10 M was used for treatments.
Immunoprecipitation and Western Blotting—Cells were harvested
24 h after transfection and lysed in Nonidet P-40 lysis buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 1
mM NaVO3, 1 mM dithiothreitol, 1 protease inhibitor cocktail, 1
mM phenylmethylsulfonyl fluoride), and the supernatants were
transferred to a new tube. Antibodies were added to the lysates,
mouse monoclonal anti-HA antibody 30 l/each, rabbit polyclonal
anti-Myc antibody 0.7–1.0 g/each, and samples were incubated
from 2 h at room temperature to overnight at 4°C. The samples were
then washed three times with cold lysis buffer. The samples were
dissolved in Laemmli buffer and analyzed by SDS-PAGE. Mem-
branes were blocked in blocking solution (1 PBS-0.1% Tween-20
with 5–10% dry milk) for 2 h before incubation with primary anti-
bodies as follows: mouse monoclonal antibodies against B23 (0.05
g/ml), actin (1:125,000), Myc (30 l/ml), or rabbit polyclonal anti-
body against ARF (0.2 g/ml) and Myc (0.07–0.2 g/ml) for 2 h at
room temperature to overnight at 4 °C. Membranes were washed
three times for 10 min each in 1 PBS-0.1% Tween-20 with shaking.
Secondary antibody was added (horseradish peroxidase-conjugated
anti-mouse (1:10,000) or anti-rabbit (1:20,000) antibodies) to the
membrane and incubated with slow shaking for 1 h at room temper-
ature. The membrane was washed three times for 10 min each with
1 PBS, 0.1% Tween-20 and 1 for 5 min with 1 PBS. Signals were
detected by ECL (Amersham Biosciences), West-Pico, orWest-Dura
(Pierce) reagents.
Immunofluorescence and Live Cell Imaging—Cultured cells were
seeded onto 6-well plates and transfected with plasmid DNA (0.3
g/well). Twenty-four hours after transfection, cells were washed two
times with 1 PBS and fixed in 4% formalin solution (Sigma Diagnos-
tics) for 10 min. Cells were then washed with 1 PBS and subsequently
in cold 1 PBS containing 0.2%Triton X-100 for 5min at 4 °C, followed
by incubation with 1 PBS containing 0.5% bovine serum albumin for
30 min prior to incubation with primary antibodies overnight. Cells
were then incubated with fluorochrome-conjugated secondary anti-
body for 30 min and were covered by anti-fluorescent mounting
medium (DAKO) and examined with an Olympus IX81 microscope
fitted with appropriate fluorescence filters. For visualization in living
cells, U2OS cells were seeded in 6-well plates followed by transfection
with plasmids encodingwild-type ormutant B23 fusedwith EGFP at the
C terminus and live cells were analyzed and photographed using the
microscope described above.
Pulse Chase Experiment for Protein Half-life Assay—U2OS cells were
seeded onto a 60-mm plate and transfected with a total of 0.7 g of
plasmid DNA. Twenty-four hours after transfection, cells were labeled
with [35S]methionine for 2 h, washed with warm 1 PBS, and chased by
culturing in Dulbecco’s modified Eagle’s medium/10% fetal bovine
serum media for the times indicated in each figure.
In Vivo Ubiquitination Assay—U2OS cells were transfected with
plasmids expressing wild-type ormutant B23 proteins with or without a
plasmid expressing HA-poly-Ub. Twenty hours after transfection, cells
were treated with 10 M (final concentration) of MG132 proteasome
inhibitor for another 10 h. After harvest, cell pellets were resuspended in
100 l of 50 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 1% SDS, 1/1000 1 M
dithiothreitol, and boiled for 10 min. To the clarified denatured lysates,
1 ml of 0.1% Nonidet P-40 lysis buffer was added followed by immuno-
precipitation and Western blotting.
In Vitro Transcription, Translation, and GST Pull-down Assay—In
vitro transcription/translation (IVT) assays were performed essen-
tially as previously described (16). Briefly, the coupled in vitro tran-
scription and translation reactions were performed using the TNT
kit as per the manufacturer’s instructions (Promega). For in vitro
binding assays individually translated proteins were mixed together
and incubated at 30 °C for 30 min to allow binding to occur. At the
end of the incubation, 200 l of Nonidet P-40 lysis buffer was added
to each binding reaction followed by immunoprecipitation with
appropriate antibodies. Expression, purification, and elution of GST
fusion proteins with glutathione were done according to the manu-
facturer’s instructions (Amersham Biosciences). For GST pull-down
assay, GST fusion proteins bound to glutathione-Sepharose 4B beads
(Amersham Biosciences) were incubated and rotated overnight at
4 °C with in vitro translated protein in binding buffer (0.1% Non-
idet P-40, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride). Fol-
lowing extensive washing in binding buffer the beads were boiled and
resuspended in SDS loading buffer and resolved on SDS-PAGE gel,
followed by gel staining with Coomassie Brilliant Blue, drying, and
autoradiography. For non-reducing SDS-PAGE as indicated, protein
samples were loaded without heating and dithiothreitol.
Cell Proliferation Assays and siRNA—Cells were seeded in 6-well
plates, and proliferation was measured by total cell count and
absorbance measurement at 595 nm on total protein (Bradford assay)
orusingacid-extractedcrystal violet stain fromfixed cells. Knocking down
B23 in 6-well plates using siRNA oligos was previously described (23).
Rescue of B23 expression was done 72 h after siRNA transfection by
GFP, B23-GFP, or mutant constructs using FuGENE 6 transfection
reagent.
Crystal Structure Modeling—The structural model of N-terminal
B23 was built on the basis of the structure ofXenopusNO38 (entry code
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1XB9, Protein Data Bank). The differences in the amino acid sequences
were mutated by the program O (48), and the orientations of the side
chains were manually adjusted in a Silicon Graphic system. The molec-
ular model and interfacial interaction were presented by the program
Ribbons (49).
RESULTS
ARF Interacts with a Short Motif in the N-terminal Oligomerization
Domain of B23—We have previously shown that the N-terminal 113
amino acid residues of B23 interact with human p14ARF (ARF thereaf-
ter) (23). This area spans the entire B23 homo-oligomerization domain
that has been mapped at residues 1–119 (50). To gain insight into the
ARF-B23 interaction, we mapped the ARF binding site in B23 in detail
using a series of B23 N-terminal deletion mutants. B23 with the first 24,
50, or 73 residues deleted retained the capacity to bind ARF, though the
binding activity of the deletion mutants appeared to decrease with pro-
gressive deletion from the N terminus (Fig. 1A). The B23 mutant with
the first 99 residues deleted (100–294) showed diminishedARF binding
ability, indicating that it was either lacking part of the B23 sequence
required for, or was otherwise interfering with, ARF binding (Fig. 1B).
Consistent with previous reports (23, 45), deletion of the first 116 resi-
dues from B23 (117–294) eliminated ARF binding (Fig. 1, B and C).
These results were identical to those obtained in an ARF-B23 in vitro
binding assay (data not shown). Thus, it appears that a short sequence
from residues 100–116 of B23 contains an element strictly required for
ARF binding. It is notable that this short region has elsewhere been
suggested to be a putative metal binding domain (51), and the region
90–117 was also found to be most important for the in vitro chaperone
activity of B23 (50).
A previous study using bacterial produced GST-B23 suggested that a
B23 fragment spanning residues 187–294 contains theARF-binding site
(46), which is at odds with this finding and with two previous studies
showing that the ARF-B23 interaction requires B23 oligomerization
domain (23) and the oligomerization and the acidic domains (45). To
determine whether experimental conditions might be a factor in the
differences, we carried out an assay using B23 produced in bacteria and
ARF produced by coupled IVT and found that a B23 C-terminal frag-
ment of 187–294 fused with GST was indeed able to interact with ARF
in vitro (Fig. 1D, lane 5). Intriguingly, however, we found that a longer
B23 fragment of 120–294was unable to interact with ARF (Fig. 1D, lane
4), consistent with our in vivo co-immunoprecipitation data (Fig. 1, B
and C). Thus, there may exist another ARF binding site in the B23 C
terminus that is masked by the N-terminal sequences and that can be
exposed under certain circumstances. In any case, we confirmed that
the binding between ARF and the B23 N-terminal oligomerization
domain is direct, as the B23 region 15–138 fused with GST is able to
strongly interact with ARF in vitro (Fig. 1D, lane 3), and because that we
could not detect B23 protein in the reticulocyte lysate used in this in
vitro assay,6 ruling out possible bridging by endogenous, full-length B23.
Identification of Residues in B23 Required for ARF Binding—
B23 (NPM or NPM1) belongs to a specific class of acidic chaperone
proteins that also includes NPM2 (52), NPM3 (53), and nucleoplasmin
(39) collectively known as the nucleoplasmin family (Fig. 2A). The
N-terminal region of B23 consists of an oligomerization domain fol-
lowed by two highly acidic regions that are separated by a bipartite
6 M. Lindstrom and Y. Zhang, unpublished observations.
FIGURE 1. ARF interacts with a short motif in the
N-terminal oligomerization domain of B23. A and
B, N terminus of B23 is required for ARF binding.
U2OS cells were either singly transfected with
plasmids encoding wild-type Myc-B23 and Myc-
tagged B23 N-terminal deletion mutants (25–294,
51–294, 74 –294, 100 –294) or cotransfected with
various B23 constructs and HA-ARF, as indicated.
Twenty-four hours after transfection, cell lysates
were prepared and immunoprecipitated with
anti-HA antibody 12CA5 (for ARF). The precipitates
were resolved by SDS-PAGE, transferred to a nitro-
cellulose membrane, and blotted with an anti-Myc
antibody 9E10 (for B23) and an anti-ARF antibody.
Approximately 10% of cell lysate was shown as load-
ing control. IP, immunoprecipitate; IB, immunoblot.
C, interaction of ARF with B23 or B23 N-terminal
deletion mutants were shown by reciprocal immu-
noprecipitation with anti-Myc antibody (for B23)
and Western blotting with anti-ARF antibody. D, in
vitro binding of 35S-labeled ARF with GST-B23. 35S-
labeled ARF protein was produced with a coupled
IVT system. Equal amounts of 35S-labeled ARF pro-
tein were incubated with bacterial produced wild-
type GST-B23 and various GST-B23 mutants as
indicated. B23-bound ARF was detected by auto-
radiography, and the B23 input was shown by
Coomassie Brilliant Blue staining. Lower frag-
ments seen represent proteolytic degradation
fragments emanating from the protease sensitive
C-terminal region of B23, whereas no degradation
is seen with the core fragment of B23-(15–138)
known to be resistant to degradation.
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nuclear localization signal (NLS) sequence. The oligomerization region
of B23 and nucleoplasmin is sometimes referred to as the “core.” The
core contains the elements necessary and sufficient for oligomerization
and is presumably the critical functional unit in all members of this
protein family (54). We have noticed that the minimal region in B23
(residues 100–116) required for ARF binding falls within the core
domain (Fig. 2A). Alignment of the core from currently known mem-
bers of the nucleoplasmin family identified several extremely conserved
residues including aGSGP sequence (Gly105–Pro108 in human B23) that
is located in middle of the ARF binding site (Fig. 2A). The GSGP
sequence (a.k.a. GSGP loop) has been implicated in playing a central
role in the formation of nucleoplasmin oligomers (40). To determine
whether the GSGP loop is involved in the ARF-B23 interaction, we
constructed B23 mutants where several of the most conserved amino
acid residueswere replacedwith alanines and tested for their interaction
with ARF. Double substitutions of Leu1023Ala and Gly1053Ala (LG)
or Ser1063Ala andGly1073Ala (SG) in B23 significantly reducedARF
binding (Fig. 2B), indicating that the GSGP loop in B23 is critically
important for mediating ARF binding. We further tested single amino
acid substitutions in the GSGP loop. Single substitutions of Leu1023
Ala or Gly1053 Ala achieved a similar effect as with the double muta-
tions in disrupting ARF binding, whereas Ser106 3 Ala did not, even
though Ser106 is highly conserved in theGSGP loop. A homology crystal
structure model of B23 built on basis of the structure of XenopusNO38
(B23 ortholog) (43) had predicted that each substitution in the GSGP
loop, except for Ser1063 Ala, would have considerable impact to the
conformation of B23 (see below), which suggested that the mutations
that disrupt ARF binding might have altered the core conformation of
B23.
Essential Role of the ARF Binding Residues for B23 Dimerization and
Oligomerization—B23 exists predominantly as an oligomer in living
cells and to a lesser extent as a free monomer (55). Because the N-ter-
minal 119 residues contain the entire B23 homo-oligomerization
domain (50), we wanted to test whether any of the B23 N-terminal
deletion and substitution mutants was still able to dimerize. We tran-
siently expressed B23 N-terminal deletion mutants in U2OS cells and
determined dimer formation between the mutant B23 and the endoge-
nous B23 by immunoprecipitation Western assays. The endogenous
B23 could be detected in transfections with Myc-tagged wild-type B23
and in the 1–192 fragment of B23 (indicated by arrows), but not in any
of the N-terminal deletion B23mutants (Fig. 3A).We noticed that dele-
tion of the C-terminal 102 residues enhanced the dimerization between
the mutant and the endogenous B23, and the reason for this remains
unclear at the moment. We further tested the GSGP loop substitution
mutants for their activity in dimerization. Consistent with findings from
crystal structure studies of other members of the nucleoplasmin family
indicating the structural importance of the GSGP loop motif (40, 42,
43), we found that the B23(LG) and B23(SG) mutants were unable to
bind endogenous B23 (Fig. 3B). Consistent results were also obtained
with bacterial produced B23 in an in vitro assay (Fig. 3C).We noted that
FIGURE 2. Identification of residues in B23
required for ARF binding. A, multiple sequence
alignment of B23 and B23-related proteins reveals
a highly conserved nucleoplasmin core in the oli-
gomerization domain and an absolutely con-
served GSGP motif (GSGP loop). Hs, Homo sapiens;
Mm, Mus musculus; Rn, Rattus norvegicus; Dr, Danio
rerio; Gg, Gallus gallus; Xl, Xenopus laevis; Dm, Dro-
sophila melanogaster; Lp, Lytechinus pictus (sea
urchin); Ap, Asterina pectinifera (starfish). B and C,
mutations in the B23 GSGP loop disrupt ARF bind-
ing. U2OS cells were either singly transfected with
plasmids encoding wild-type Myc-B23 and Myc-
tagged B23 mutants or cotransfected with various
B23 constructs and HA-ARF, as indicated. Immu-
noprecipitation and Western blotting assays were
performed essentially the same as described in
Fig. 1. LG, double substitutions of Leu102 3 Ala
and Gly105 3 Ala; SG, double substitutions of
Ser1063 Ala and Gly1073 Ala.
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B23-(1–113) mutant was attenuated in binding to GST-B23 (Fig. 3C).
The reason for this remains unclear, but it could be due to the B23-(1–
113) mutant lacks the last residues within the conserved B23 oligomer-
ization domain. Notably, B23-(1–113) mutant can still bind with ARF
both in vivo and in vitro (23) (data not shown). We also detected weak
residual in vitro dimerization between B23-(25–294) and wt GST-B23.
Thus, B23-(1–113) and B23-(25–294) deletion mutants behave hypo-
morphic, displaying different binding to itself versus wt B23, and also
depending on the experimental system.
To determine whether the non-dimeric B23(LG) mutant also was
defective in forming homo-oligomers, B23 protein was produced with
either an IVT system or in bacteria as a GST-tagged fusion protein and
was loaded on gels without prior boiling of the samples in SDS loading
buffer. Under these conditions, the B23 oligomer was readily observed
as a distinct band near the top of the gel greater than 220 kDa (Fig. 3, D
and E). In contrast, the B23(LG) and the B23-(25–294) mutants were
unable to form oligomers (Fig. 3,D and E). Together, these results show
that the residues in B23 essential forARFbinding are also critical for B23
to form oligomers.
Modeling of B23 Core Mutants—To gain further insight into the role
of the GSGP loop in mediating ARF binding, we modeled the structural
basis of the B23(LG) mutant. A homology model of B23 was built on
basis of the structure of NO38 core domain (43). From the high
sequence homology betweenNO38 and human B23, we believe that the
structure of B23 not only has a similar topological folding as that of
NO38, but also forms a pentamer in the crystal state (Fig. 4A). The
model shows that the GSGP loop was located on the surface of the
monomer and pentamer of B23. However, the GSGP loop does not
directly contribute to the interfacial interactions of the dimer or pro-
posed decamer structure. Therefore, the impact of the mutations of
L102A, G105A, and G107A on dimerization or oligomerization of B23
must be achieved via conformational changes within the monomeric
B23. A careful examination of the model structure shows that Leu102 is
a key contributor, together with Leu23 and Val109, in forming the hydro-
phobic core of B23. Thus, a Leu1023 Ala mutation would significantly
weaken the hydrophobic interactions between the GSGP loop and
Leu23/Val109 pocket and thus impact the conformation of B23 and the
formation of oligomers. Gly105 has 104o and 149o for its backbone con-
formational angles of and , andGly107 has and  of 81o and171o.
These angles are allowed only for glycine. Thus, the Gly105 3 A and
Gly1073 Ala mutations would dramatically impair or even destroy the
B23 monomeric -barrel and thus the formation of oligomers. On the
other hand, the structural model would predict no significant impact of
the Ser106 3 Ala mutation on the conformation of the B23 -barrel
because Ser106 has conformational angles of 77o and 30o, which
allow for the replacement of alanine without impact on the B23 confor-
mation. These predictions are completely consistent with the experi-
FIGURE 3. Essential role of the ARF binding res-
idues for B23 dimerization. A, homodimer for-
mation between ectopically expressed Myc-B23
and endogenous B23. U2OS cells were singly
transfected with plasmids encoding wild-type
Myc-B23 and various B23 deletion mutants. Immu-
noprecipitation and Western blotting were per-
formed as described in the legend to Fig. 1, except
that a mixture of anti-B23 and anti-Myc antibodies
were used in the immunoblotting, as indicated.
The ectopically expressed B23 was detected by
anti-Myc antibody 9E10 whereas endogenous B23
was detected using an anti-B23 antibody. Arrows
indicate endogenous B23 co-immunoprecipitated
by Myc-B23. B, GSGP loop mutations inhibit B23
oligomerization. U2OS cells were singly trans-
fected with plasmids encoding wild-type Myc-B23
and Myc-tagged B23 GSGP loop substitution
mutants, as indicated. C, in vitro interaction of GST-
B23 and 35S-labeled B23 mutants. B23 protein was
produced with a coupled IVT system or from bac-
teria as a GST-tagged protein. Equal amount of
GST-B23 protein was incubated with 35S-labeled
wild-type B23 and various B23 mutants as indi-
cated. GST-B23-bound radioactive B23 was
detected by autoradiography. Input for 35S-la-
beled B23 and GST-B23, are shown by autoradiog-
raphy and Coomassie Blue staining respectively.
Lower molecular weight bands seen in lanes with
wt B23, B23-(25–294), B23-(1–192), and B23(LG)
mutants represent initiation of translation in vitro
from downstream methionine residues in B23 (in
particular M1, M7), given that the Myc tag is placed
at the N terminus and the first ATG (M1) in B23
cDNA is retained. D, homo-oligomer formation of
B23 and B23 N-terminal mutants. Myc-B23 was in
vitro translated in the presence of [35S]methi-
onine. The samples, without prior heating in SDS
loading buffer so as to preserve the oligomer, were
separated on an SDS-PAGE gel, and the results
analyzed by autoradiography. E, homo-oligomer
formation was analyzed essentially the same as in
D except experiment was conducted with GST-
B23 proteins.
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mental results of Fig. 3, and suggest that the conformation of the B23
core domain is critical for mediating ARF binding.
Non-oligomeric B23 Delocalizes from the Nucleolus—Normally, B23
localizes to the nucleolus. The mechanisms governing the nucleolar
localization of B23 are unknown, although it has been suggested that
B23 nucleolar localization is closely associated with the states of cell
growth and RNA synthesis (56). To find out whether there is a potential
link between B23 oligomerization and its nucleolar localization, we
determined the subcellular location of the variousMyc-tagged B23 pro-
teins in transiently transfected U2OS cells by immunofluorescence
staining with an anti-Myc antibody. The B23 N-terminal deletion
mutant lacking the first 24 residues, as well as the other mutants with
progressive N-terminal deletions delocalized from the nucleolus and
were distributed throughout the nucleus (Fig. 5A, panels 1–3 and data
not shown). The B23-(196–294) mutant lacking both the oligomeriza-
tion domain and the nuclear localization signal (NLS) (50) dispersed
throughout the nucleus and cytoplasm (Fig. 5A). Notably, nucleolar
staining was still clearly visible in cells expressing the N-terminal dele-
tion mutants, indicating that the proteins are not excluded from the
nucleolus. This was in particular true for B23-(25–294)mutant that also
showed residual binding to GST-B23 in vitro (Fig. 3C) although this
interaction was not seen in the co-immunoprecipitation experiment. In
contrast, the B23 C-terminal deletion mutants (1–113) and (1–192)
showed nucleolar localization, but with increased nucleoplasmic stain-
ing than seen in wt B23-transfected cells (Fig. 5A, panels 5 and 6). These
results are consistent with the notion that the activity of B23 oligomer-
ization correlates with its nucleolar accumulation. In further support of
this notion, B23 mutants with GSGP loop substitutions disrupting oli-
gomerization delocalized from the nucleolus (Fig. 5B, panels 2–5),
whereas the B23 mutant that did not affect oligomerization (S106A)
remained in the nucleolus (Fig. 5B, panel 6). To further confirm these
findings we fused wt B23 and B23(LG) mutant with GFP and analyzed
the localization in living cells. In agreementwith results using fixed cells,
wt B23-GFP, but not the B23(LG)-GFPmutant, accumulated in nucleoli
of living cells (data not shown). We noticed that the B23-(1–113) frag-
ment lacking the NLS, yet localized to the nucleolus (Fig. 5A, panel 5).
We believe this is due to its ability to oligomerize with endogenous B23.
Indeed, B23-(1–113) displayed a weak binding to wt GST-B23 as in the
in vitro binding assay (Fig. 3C). The results of each of the B23 mutant
ability to interact with ARF, to form oligomers, and to localize to the
nucleolus are summarized in Fig. 5C.
B23(LG) Mutant Is Defective in Restoring Cell Growth—To study the
B23 and B23(LG) mutant functions in cell growth and proliferation, we
used siRNA-mediated knockdown of endogenous B23 in U2OS cells
followed by rescue with transient expression of GFP-tagged B23 (B23-
GFP) or B23(LG) mutant (B23(LG)-GFP). Knockdown of endogenous
B23 in U2OS cells impairs cell growth as measured by total cell count
(Fig. 6A). On the other hand, ectopic expression of B23-GFP and
B23(LG)-GFP slightly, but reproducibly, promoted cell growth (Fig. 6B).
In this setting where endogenous B23 is still kept at a normal level there
was no major difference between the B23(LG)-GFP mutant and B23-
GFP. Interestingly, in cells depleted of endogenous B23 with siRNA the
wild-type B23was able to restore cell growth,whereas the B23(LG)-GFP
mutant was not (Fig. 6C), indicating that the non-oligomeric B23(LG)
mutant is defective in promoting cell growth.
It has been shown that B23 plays a critical role in controlling centro-
some duplication and genomic stability (25, 38). To further study the
functional consequences of the B23(LG) mutant, we examined nuclear
integrity of cells expressing the mutant protein by scoring cells with
aberrant nuclear structure. We noticed that most cells expressing B23-
GFP exhibited normal nuclear appearance (Fig. 6,D and E). In contrast,
a significant fraction (15%) of cells expressing the B23(LG) mutant
showed striking nuclear abnormalities, such as multiple or bi-lobed
nuclei and abnormally shaped nuclei (Fig. 6, D and E). This high fre-
quency of nuclear abnormalities was not seen in GFP- (data not shown)
or B23-GFP-transfected cells.
Non-oligomeric B23 Is Unstable—B23 is a stable protein with a half-
life greater than 24 h (23). One of the probable reasons for this stability
could be its localization in the nucleolus, where no protein degradation
has been found. With the finding that the non-oligomeric B23 delocal-
izes from the nucleolus, we wanted to determine whether there is a link
between nucleolar localization and B23 stability. To this end, we
determined the half-life of B23 with a pulse chase experiment. The
B23 proteins were transiently expressed in U2OS cells, pulse-labeled
with [35S]methionine, and the protein half-life was chased for up to 40 h.
Consistent with previous observation (23), the wild-type B23 was a sta-
ble protein, with a half-life greater than 32 h (Fig. 7A). The C-terminal
deletion mutant B23 (1–192) was also a very stable protein with a half-
life at least as long as that of the wild-type B23 (Fig. 7A). In contrast, B23
mutants withN-terminal deletions orGSGP loopmutationsweremuch
shorter lived relative towt B23,with half-lives around 10 h (Fig. 7A). The
half-lives of these non-oligomeric B23 mutants were similar to the half-
FIGURE 4. Ribbon diagram of B23 model. A, B23 pentamer. B, B23 monomer. The GSGP loop is shown in the stickball model. C, detailed view of the GSGP environment, where Leu102
contributes to formation of the hydrophobic core of the B23 molecule.
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life of a wild-type B23 with ARF overexpression, which has been deter-
mined to be about 12 h (23). Thus, B23 mutants that are unable to
oligomerize delocalize from the nucleolus and are more rapidly
degraded.
To determine whether nucleolar localization and oligomerization are
both required for B23 to be a stable protein, we took advantage of treat-
ing cells with a low concentration of actinomycin D (5 nM), which is
known to delocalize B23 from the nucleolus (57). U2OS cells were
treated with 5 nM actinomycin D for 12 h to induce a delocalization of
B23, followed by a B23 half-life assay. The actinomycin D treatment
delocalized endogenous B23 from the nucleolus to the nucleoplasm
(Fig. 7B), a location reminiscent of that of mutant B23 with GSGP loop
mutations (Fig. 5B). The treatment did not affect B23 dimerization as
determined by dimer formation between endogenous B23 and trans-
fected Myc-tagged B23 (Fig. 7C), suggesting that B23 dimerization can
occur outside of the nucleolus. In addition, under these conditions the
B23(LG)mutant and the endogenous B23 co-localized to the same com-
partment, yet they did not interact, further confirming the lack of
dimerization activity of the B23(LG) mutant. Nor did actinomycin D
treatment affect the B23 steady state level as determined by a Western
assay (Fig. 7D), or its half-life as indicated by a 35S pulse-chase assay (Fig.
7E), demonstrating that delocalization from the nucleolus per se does
not trigger rapid degradation of B23. Hence, the decreased half-life of
the non-oligomeric B23 mutants most likely resulted from their inabil-
ity to form oligomers together with a nucleoplasmic localization. How-
ever, we cannot rule out the effect of conformational changes on B23
stability, which occur hand-in-hand with a failure to oligomerize. Iden-
tification of a monomeric B23 mutant that retains a wild-type confor-
mation could resolve this issue but remains a formidable challenge if
even possible. Finally, we noticed that the half-life of the endogenous
B23was longer than that of transfectedwild-type B23 (compare Fig. 7,A
with E). This is presumably because of the fact that endogenous B23
could more efficiently form oligomers than the transfected B23, which
may have been expressed at a non-physiological high level.
The increased instability of B23 core mutants could be due to increased
ubiquitination and proteasomal degradation. To test this possibility, U2OS
cells were transfected with plasmids encoding wt B23 or B23(LG) mutant.
After 20 h, cells were treated for an additional 6 hwithMG132 proteasome
inhibitor followedbyharvestdirectly intoLaemmli samplebufferwithSDS.
As can be seen in Fig. 8A, wt B23 remained stable and changed very little in
level in response toMG132treatment. Incontrast, theB23(LG)mutantwas
readily stabilized byMG132, suggesting that the instability of the B23 core
mutants is at least in part mediated through proteasomal degradation. To
further investigate the putative role of proteasome-mediated degradation
ofB23 coremutants, an in vivoubiquitination assayswas carriedout.U2OS
cells were co-transfected with plasmids encoding HA-tagged poly-ubiq-
FIGURE 5. Non-oligomeric B23 delocalizes from
the nucleolus. A, B23 N-terminal deletion
mutants delocalize from the nucleolus. U2OS cells
were singly transfected with indicated Myc-
tagged B23 plasmids. 24 h after transfection, cells
were fixed and immunofluorescence-stained with
a rabbit anti-Myc antibody followed by staining
with Texas-red-conjugated donkey anti-rabbit
secondary antibody. Phase contrast images are
also shown. B, B23 GSGP loop mutants delocalize
from the nucleolus. The assay was performed
essentially the same as in A. C, schematic represen-
tation of the ARF binding, oligomerization, and
nucleolar localization properties of various Myc-
B23 mutants. The ARF binding site on B23 (resi-
dues 100 –116) is indicated.
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uitin and B23 or B23 mutants followed by denaturing cell lysis and immu-
noprecipitation. Before harvest, all samples were treated with MG132 to
allow accumulation and detection of B23 ubiquitin conjugates. Under nor-
mal conditions the level of ubiquitin conjugation to wt B23 was low or
undetectable even after 10 h of treatment withMG132, in agreement with
the long half-life and nucleolar localization of B23 (Fig. 8B). In contrast,
GSGP loopmutants B23(SG) and B23(LG) displayed amarkedly increased
level of ubiquitination (Fig. 8B).We conclude that B23GSGP loopmutants
are less stable relative to wt B23 because of increased ubiquitination and
proteasome-mediated degradation.
DISCUSSION
It has recently been shown by several groups that the tumor suppres-
sor ARF interacts with the nucleolar protein B23/NPM (23, 44–46).
Although these studies agreed upon mapping of the ARF N-terminal as
the binding domain, they came to distinct conclusions about the region
in B23 that is required for the interaction. Bertwistle et al. (45) suggested
a direct binding to the acidic domain with a requirement for the oli-
gomerization domain, Itahana et al. pinpointed the N-terminal region
1–113 (23), whereas Korgaonkar et al. (46), using an in vitro binding
assay, suggested a region in B23-(187–295) known to harbor the het-
erodimerization and nucleic acid binding domains. We noted several
potential problems in mapping the ARF binding site on B23. The first
problem is the tendency of binding of the exogenous B23 to endogenous
B23 through the oligomerization domain so that the endogenous B23
might bridge ARF to the exogenous B23; such an interaction might
cause confusion if the results are not interpreted cautiously, as also
pointed out by Korgaonkar et al. This is particularly a problem when
taking into consideration that the endogenous B23 is a highly abundant
protein in the cell, expressed at similar or higher levels than ectopically
expressed B23 (see Fig. 3). Second, B23 exists in large RNP complexes;
therefore proteins that do not bind directly can be linked and immuno-
precipitated through RNA and other proteins in mild IP conditions.
Third, localization of B23 mutants (nucleolus versus nucleoplasm) and
fourth, the binding stoichiometry of oligomeric versusmonomeric B23
might also affect the readout in an immunoprecipitation assay.
To initially clarify the ARF-B23 binding issue and to use ARF as a
binding substrate for the continued study of B23 function, we generated
a broad series of B23 deletion mutants and carried out both in vivo and
in vitro binding assays in an attempt to define the ARF binding site on
B23. Bertwistle et al. (45) suggested that ARF binds the acidic regions in
B23 with an “undefined contribution” from the oligomerization
domain. We found that this “undefined contribution” can be narrowed
down to B23 amino acid residues 100–117. We also confirmed our
previous study showing that ARF can directly bind the B23 oligomer-
ization domain (see below) without the presence of the acidic regions.
However, our data cannot rule out the possibility that the acidic patches
may increase and stabilize the ARF binding.We also demonstrated that
ARF is able to bind monomeric B23, by using several B23 N-terminal
deletion mutants, which are devoid of dimerization/oligomerization.
The C-terminal region of B23 could contain another ARF binding site,
since we confirmed that a fragment of 187–294 of B23 interacted with
ARF in an in vitro GST pull-down assay, consistent with the finding by
Korgaonkar et al. (46). However, we observed binding of the C-terminal
fragment of B23with ARF only when B23was produced as aGST fusion
protein and mixed with in vitro translated ARF. In vitro translated B23-
(187–294) fragment did not interact with GST-ARF whereas the N-ter-
minal region of B23-(1–113) was able to do so (data not shown). It is
possible that the recombinant B23 mutant produced in vitromight not
be properly modified and/or folded, creating an aberrant interaction
with ARF. Supporting this view, interaction with ARF is not really evi-
dent with the GST-B23-(120–294) fragment (Fig. 1D).
Having established the importance of the B23 region 100–117 inARF
binding, we made a comparative sequence alignment analysis of multi-
ple members of the nucleoplasmin family. Intriguingly, this region
turned out to be the most conserved region in the whole nucleoplasmin
FIGURE 6. B23 mutant is defective in restoring cell growth. A, knockdown of B23 in U2OS cells with a B23 siRNA oligo impairs cell growth. Data presented as relative cell number
seen in siB23 oligo-transfected cells compared with control cells transfected with scrambled siRNA (siScr) set to 100%, 72 h after siRNA transfection. An average of three experiments
is shown. B, transient expression of B23-GFP, B23(LG)-GFP but not GFP alone in U2OS cells promote cell growth. U2OS cells were transfected with indicated plasmid DNA for 24 h and
analyzed using absorbance 595 nm measurements (Bradford assay) of total protein. Shown is one representative experiment in triplicate, and data are presented relative to
GFP-transfected cells. A.U., arbitrary units. C, depletion of B23 in U2OS cells with a B23 siRNA or a control siRNA (siScr) for 72 h was followed by transfection with B23-GFP, B23(LG)-GFP,
or GFP alone. Data were presented as in B. Transfection of GFP or control siRNA did not have discernible effect on cells (data not shown). D, 24 h after transfection of U2OS cells with
GFP, B23-GFP or B23(LG)-GFP plasmids, cells were fixed and counterstained with DAPI. Cells expressing B23(LG)-GFP but not B23-GFP displayed nuclear abnormalities such as
multiple or bi-lobed nuclei, abnormally shaped or enlarged nuclei. E, quantification of immunostaining data in D, presented as the percentage of transfected cells showing nuclear
abnormalities for GFP, B23-GFP, or B23(LG)-GFP. At least 400 transfected cells were counted and analyzed for each construct. Shown is one representative experiment in triplicate.
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superfamily, although some other parts of the core are also well con-
served. Initial experiments were aimed at mutating single amino acid
residues in this region followed by analysis of binding with ARF. We,
however, also noted a number of intriguing features with thesemutants.
Not only did some of them lose the ability to bind ARF in vivo, but they
also showed a striking delocalization from the nucleolus to the nucleo-
plasm, were less stable than thewild-type protein, and failed to dimerize
both in vivo and in vitro. Based on our data, a reasonable model con-
cerning ARF-induced B23 degradation can be proposed: ARF, through
interacting with the GSGP loop in B23, might interfere with B23 dimer-
ization/oligomerization, perhaps by inducing conformational changes
or through steric hindrance. The non-oligomeric B23may then delocal-
ize to the nucleoplasm and undergo proteolytic degradation. That the
GSGP loop mutant B23(LG) was defective in forming functional oli-
gomers similar towt B23was confirmed by usingGSTpull-down assays,
in vitro translation product analysis followed by non-reducing SDS-
PAGE and co-immunoprecipitation assays. In support, we alsomodeled
the structural basis of the B23 mutants, based on the structure of the
Xenopus B23 homolog NO38 core domain (43). Predictions obtained
from the structure modeling were consistent with the experimental
results. In addition the modeling also suggested that it is the conforma-
tion of the B23 core domain, but may be not individual amino acid
residues within, that is critical for mediating ARF binding. Given the
strong similarity between the primary sequences and secondary struc-
tures of the GSGP loop among the nucleoplasmin family members, it
would be of interest to find out whether ARF interacts with other mem-
bers of the family. Indeed, we have found that ARF also interacts with
NPM3 in a B23-free system (data not shown) and importantly, NPM3
FIGURE 7. Non-oligomeric B23 is unstable. A, half-life determination of various B23
proteins. U2OS cells were singly transfected with plasmids encoding Myc-tagged wild-
type B23 (wt), the C-terminal deletion mutant B23-(1–192), the GSGP loop substitution
mutant B23(LG), and N-terminal deletion mutants B23-(25–294), B23-(100 –294), and
B23-(117–294). Twenty hours after transfection, cells were pulse-labeled with [35S]me-
thionine for 2 h and then chased for the indicated length of time. Cell lysates were
immunoprecipitated with an anti-Myc antibody. The resulting B23 immunoprecipitates
were separated by SDS-PAGE and visualized by autoradiography. The amount of labeled
B23 protein at each time point was quantified on a PhosphorImager and normalized
relative to the amount of radiolabeled B23 present in cells following the 0 h chase; results
are plotted. B, localization of endogenous B23 in U2OS cells after treatment with 5 nM
actinomycin D for 12 h. Immunofluorescence staining was performed essentially the
same as described in Fig. 5. C, U2OS cells were singly transfected with plasmids encoding
the Myc-tagged wt B23, C-terminal deletion mutant B23-(1–192), or GSGP loop mutant
B23(LG). Twenty-four hours after transfection, cells were either untreated () or treated
() with 5 nM actinomycin D. Immunoprecipitation and Western blotting assays were
performed essentially the same as described in the legends to Figs. 1 and 2. D, level of
endogenous B23 was not affected by 5 nM actinomycin D treatment for 12 h. E, B23
half-life assay after 5 nM actinomycin D treatment. U2OS cells were treated with 5 nM
actinomycin D for 6 h; cells were then pulse-labeled with [35S]methionine for 2 h and
chased for the indicated length of time. Cell lysates were assayed as described above.
FIGURE 8. Ubiquitination of B23 GSGP-loop mutants. A, MG132 treatment stabilizes
B23(LG) mutant but not wild-type B23. U2OS cells were transfected with plasmids
encoding wt B23 or B23(LG) mutant together with GFP as a transfection marker. After
20 h, the transfected cells were treated with or without MG132 for an additional 6 h.
Following whole cell extract preparation in SDS buffer the lysates were analyzed by
Western blot using antibodies against Myc, GFP, or actin. One out of three experiments,
with similar results is shown. B, in vivo ubiquitination of B23 GSGP loop mutants. U2OS
cells were transfected with plasmids encoding wt B23, B23(LG), or B23(SG) mutants in
combination with a plasmid for HA-tagged polyUb as indicated. Myc-tagged B23 from
denatured cell lysates was immunoprecipitated with a rabbit polyclonal antibody
against Myc followed by immunoblot against ubiquitin (anti-HA), Myc-B23, actin or GFP.
In this experiment all samples were treated with 10 M MG132 for 10 h before harvest.
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lacks the C-terminal region that is unique to B23 (53), further indicating
that ARF can interact with B23 in the absence of its C terminus. It is
conceivable that mutations in the GSGP loop motif also would render
other members of the NPM family functionally handicapped.
The mechanisms that control nucleolar localization of B23 appear to
differ from other nucleolar proteins. Our findings confirm the notion
that the nucleolar localization of B23 requires multiple functional ele-
ments besides the NLS and the basic cluster motif in the C terminus,
since we found that there is also an intimate link between nucleolar
accumulation and a functional oligomerization domain. Our analysis of
B23 N-terminal and GSGP loop motif mutants shows that those
mutants that are unable to form oligomers also are impaired in nucleo-
lar accumulation, although not strictly excluded from nucleoli. How-
ever it can be argued, that it is not possible to distinguish between the
possibility that non-oligomeric B23 mutants also have a defective con-
formation that in turn prevents binding to nucleolar target proteins or
that oligomerization per se is required for B23 nucleolar accumulation.
Interestingly, our work suggests an alternative explanation to the nucle-
oplasmic localization of B23(L102A) mutant as noted and described
elsewhere (58, 59). We here suggest that the nucleolar delocalization of
B23(L102A) mutant is caused by defective oligomerization and/or con-
formational changes in B23. Although our data do not rule out that
Leu102 acts within a putative B23 nuclear export sequence IXXPXXLXL
within residues 94–102, the fact that B23(L102A) localization were
mimicked by our mutants B23(G105A) and B23(G107A) is intriguing.
We found that both oligomeric wild-type B23 and B23(LG) mutant
both stimulated an increase in S-phase fraction and behaved similar in a
long-term cell growth assay. These results suggest that B23(LG)mutant
retains some of its functions and is not a “dead” mutant. Instead, the
B23(LG) mutant is primarily defective for binding ARF and possibly
other basic proteins in vivo, whereas also having a localization defect.
Our data are in agreement with the established multifunctional nature
of B23. For instance, the C-terminal region of B23 can bind DNA or
RNA (60), whereas on the other hand, the chaperone function has been
linked to theN-terminal region (50). Taken together, our data show that
the highly conserved GSGP loop in the core domain of B23 is essential
formediating bothARF binding and have an essential role in controlling
aspects of B23 protein structure, stability, and localization.
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